Among active 13F managers last quarter, 11 opened and none reduced or exited; the largest holder to move was Great Point Partners LLC (new position). Over the last 180 days, 1 insider bought and none sold, a net $0 in open-market trades.
Funds lean in and no leg opposes.
18 tracked 13F filers disclose a position in SCYX as of the latest SEC 13F filings, a combined $14.0M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Great Point Partners LLC | 944K | $3.8M | ▲New +944K sh | Q2 2026 | |
| 2 | Squadron Capital Management LLC | 757K | $3.1M | ▲New +757K sh | Q2 2026 | |
| 3 | Woodline Partners LP | 388K | $1.6M | ▲New +388K sh | Q2 2026 | |
| 4 | Vanguard Capital Management LLC | 297K | $1.2M | ▲New +297K sh | Q2 2026 | |
| 5 | Avidity Partners Management LP | 260K | $1.1M | ▲New +260K sh | Q2 2026 | |
| 6 | Kingdon Capital Management, L.L.C. | 248K | $1.0M | ▲New +248K sh | Q2 2026 | |
| 7 | Heights Capital Management, Inc | 151K | $613K | ▲New +151K sh | Q2 2026 | |
| 8 | DAFNA Capital Management LLC | 136K | $553K | ▲New +136K sh | Q2 2026 | |
| 9 | Geode Capital Management, LLC | 82K | $334K | ▲New +82K sh | Q2 2026 | |
| 10 | Vanguard Fiduciary Trust Co | 58K | $236K | ▲New +58K sh | Q2 2026 | |
| 11 | BlackRock, Inc. | 42K | $169K | ▲New +42K sh | Q2 2026 | |
| 12 | Velan Capital Investment Management LP | 40K | $163K | ▲New +40K sh | Q2 2026 | |
| 13 | Bridgeway Capital Management, LLC | 16K | $63K | ▲New +16K sh | Q2 2026 | |
| 14 | Wealth Effects LLC | 14K | $56K | ▲New +14K sh | Q2 2026 | |
| 15 | Vanguard Global Advisers, LLC | 936 | $4K | ▲New +936 sh | Q2 2026 | |
| 16 | HighMark Wealth Management LLC | 132 | $537 | ▲New +132 sh | Q2 2026 | |
| 17 | Cornerstone Planning Group LLC | 37 | $146 | ▲New +37 sh | Q2 2026 | |
| 18 | SBI Securities Co., Ltd. | 29 | $118 | ▲New +29 sh | Q2 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 11 funds opened a new position in SCYX, while none reduced or exited. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Proqr Therapeutics NVPRQR | 6 funds | $17.0M |
| Nvidia CorpNVDA | 5 funds | $1.7B |
| Cytokinetics IncCYTK | 5 funds | $121.8M |
| Syndax Pharmaceuticals IncSNDX | 5 funds | $89.5M |
| Annexon IncANNX | 5 funds | $61.4M |
| Enliven Therapeutics IncELVN | 5 funds | $57.2M |
| Compass Pathways PLCCMPS | 5 funds | $51.0M |
| Dexcom IncDXCM | 5 funds | $48.8M |
| Illumina IncILMN | 5 funds | $30.5M |
| Delta Air Lines IncDAL | 5 funds | $23.0M |
| Tenax Therapeutics IncTENX | 5 funds | $20.5M |
| Neurogene IncNGNE | 5 funds | $17.1M |
Ranked by how many of SCYX's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in SCYX.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Apr 1, 2026 | Angulo Gonzalez David | Chief Executive Officer, Director | Buy (P) | 109K | — |
| Sep 12, 2024 | Angulo Gonzalez David | Chief Executive Officer, Director | Buy (P) | 20K | $27K |
| Apr 26, 2022 | Sukenick Scott | General Counsel | Buy (P) | 4K | $11K |
| Apr 26, 2022 | Taglietti Marco | Chief Executive Officer, Director | Buy (P) | 75K | $225K |
| Jan 22, 2021 | Perceptive Life Sciences Master Fund Ltd | 10% Owner | Sell (S) 2 lots, same day | 319K | $2.6M |
| Jan 21, 2021 | Perceptive Life Sciences Master Fund Ltd | 10% Owner | Sell (S) | 95K | $701K |
| Jan 20, 2021 | Perceptive Life Sciences Master Fund Ltd | 10% Owner | Sell (S) | 185K | $1.4M |
| Dec 21, 2020 | Angulo Gonzalez David | Chief Medical Officer | Buy (P) | 2K | $10K |
| Dec 21, 2020 | Anido Armando | Director | Buy (P) | 5K | $31K |
| Dec 21, 2020 | Francois Eric | Chief Financial Officer | Buy (P) | 600 | $4K |
| Dec 21, 2020 | Gilman Steven C | Director | Buy (P) | 4K | $25K |
| Dec 21, 2020 | Macdonald Guy | Director | Buy (P) | 8K | $50K |
One row per insider, day and transaction code; shares and value are summed across the lots. Every lot is on the full insider page and in the filing.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 0 | 0 | – |
Insiders Form 4 open-market | 1 | 0 | $0 |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
| Class | 13F holders | Value held |
|---|---|---|
| SCYXthis pageCommon Stock | 18 funds | $14.0M |
| SCYXEURCOM NEW | 18 funds | $1.2M |
| 811292101Stock | 1 funds | $11 |
Same issuer, multiple share classes. The consensus leaderboards count this company once across all classes; this is the per-class detail.
Connected entities for SCYX
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/SCYX/capital-change-brief"
Use Arkolith's capital_change_brief for SCYX. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for SCYX. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.